reports
AtaiBeckley Announces Positive Topline Results from an Exploratory Pha...
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profileEMP-01 demonstrated a clinically meaningful placebo-adjusted least squares mean reduction of 11.85 points on the Liebowitz Social Anxiety Scale (LSAS) at Day 43 (Hedges’ g = 0.45; p-value = 0.036, one-tailed)EMP-01 demonstrated a robust separation from placebo on the Clinician Global Impression–Improvement (CGI-I) asses...
Pennant Reports Fourth Quarter and Fiscal Year 2025 Results
Pennant Reports Fourth Quarter and Fiscal Year 2025 Results Conference Call and Webcast scheduled for tomorrow, February 26, 2026 at 10:00 am MT EAGLE, Idaho, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced its operating results, reporting GAAP diluted earnings per share of $0.84 for the full year and $0.24 for the fourth quarter of 2025. Pennant also reported adjusted diluted earnings per share of $1.18 for the full year and $0.34 for the qua...
- Dave Nicoski
- Ross LaDuke
POST POST HOLDINGS INC.
ENSG ENSIGN GROUP INC.
DGED DIAGEO PLC (ADR)
BKU BANKUNITED INC.
ACD ADECOAGRO S.A.
FDP FRESH DEL MONTE PRODUCE INC.
BF.B BROWN-FORMAN CORPORATION CLASS B
SENEA SENECA FOODS CORP. CL A
NOMDN NOMAD FOODS LTD.
SPB SPECTRUM BRANDS HOLDINGS INC.
PNTG PENNANT GROUP
PACS PACS GROUP INC
NHC NHC COMMUNICATIONS INC COM
- Jonathan Moreland
AtaiBeckley To Host Virtual Investor Day on March 6, 2026
AtaiBeckley To Host Virtual Investor Day on March 6, 2026 NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET. The event will feature presentations and live Q&A sessions with members of the Company’s executive leadership team and several external key opinion leaders....
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
ACN ACCENTURE PLC CLASS A
WK WORKIVA
WDAY WORKDAY INC. CLASS A
THRM GENTHERM INCORPORATED
SXT SENSIENT TECHNOLOGIES CORPORATION
SFM SPROUTS FARMERS MARKETS INC.
NSP INSPERITY INC.
HTGC HERCULES CAPITAL INC.
GPC GENUINE PARTS COMPANY
FELE FRANKLIN ELECTRIC CO. INC.
EXTR EXTREME NETWORKS INC.
EXPE EXPEDIA GROUP INC.
CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION CLASS A
CRY CRYOLIFE INC.
CPRT COPART INC.
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ATRC ATRICURE INC.
STN. STANTEC INC
TLX TALANX AG
FLTR FLUTTER ENTERTAINMENT PLC
BRO BROWN & BROWN INC.
SLM SLM CORP
TREE LENDINGTREE INC.
USLM U.S. LIME & MINERALS
WCN WASTE CONNECTIONS INC.
GIB.A CGI INC. CLASS A
CHWY CHEWY INC. CLASS A
QS QUANTUMSCAPE
SOFI SOFI TECHNOLOGIES INC
BWMN BOWMAN CONSULTING GROUP LTD
TPG TPG INC
SMR NUSCALE POWER CORP
ALAB ASTERA LABS INC
CAI CARIS LIFE SCIENCES INC
PTRN PATTERN GROUP INC.
LCID LUCID GROUP INC.
GDYN GRID DYNAMICS HOLDINGS INC.
APPE1 ASAN PARDAKHT PERSIAN ORD
AtaiBeckley Appoints Michael Faerm as Chief Financial Officer
AtaiBeckley Appoints Michael Faerm as Chief Financial Officer NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the appointment of Michael Faerm as Chief Financial Officer, effective March 9, 2026. Mr. Faerm is a seasoned financial executive with more than 25 years of experience across life sciences companies, equity research, and investment banking. As Chie...
AtaiBeckley To Participate in Upcoming Investor Conferences
AtaiBeckley To Participate in Upcoming Investor Conferences NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that Srinivas Rao, M.D., Ph.D., Co-Founder and Chief Executive Officer, and Jason Awe, Ph.D., Vice President of Investor Relations, will participate in fireside chats and host one-on-one meetings at the following investor conferences in March. TD Cowen ...
Pennant Announces Fourth Quarter and Year-End 2025 Earnings Release an...
Pennant Announces Fourth Quarter and Year-End 2025 Earnings Release and Call EAGLE, Idaho, Feb. 12, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, announced today that it expects to issue its fourth quarter and fiscal year 2025 financial results on Wednesday, February 25, 2026. Pennant invites current and prospective investors to tune into a live webcast to be held the following day, Thursday, February 26, 2026, at 10:00 a.m. Mountain Time (12:00 p.m. Eastern Time)...
AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scie...
AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced its participation in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), which took place on January 12 - 15, 2026 in Nassau, The Bahamas. The Company present...
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan ...
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today provided its outlook for 2026 ahead of attendance at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, California, on January 12 – 15, 2026. Dr Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBe...
AtaiBeckley Completes Redomiciliation to the United States
AtaiBeckley Completes Redomiciliation to the United States NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced the completion of the redomiciliation of the parent company of the AtaiBeckley group from a Netherlands company to a U.S. entity incorporated in Delaware. The redomiciliation was approved by approximately 99% of the votes cast at the Company’s extra...
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI) NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced its common stock has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 22, 2025. “2025 has been a defining year for AtaiBeckley, marked by meaningful progress across our pip...
AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthenin...
AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio NEW YORK and AMSTERDAM, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that the United States Patent and Trademark Office has granted a new patent covering EMP-01 (oral R-MDMA), further strengthening the company’s intellectual property estate and long-term...
Sensient Technologies Corp: 1 director
A director at Sensient Technologies Corp sold 4,518 shares at 94.809USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
- Jonathan Moreland
RGP RESOURCES CONNECTION INC.
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FAST FASTENAL COMPANY
TZOO TRAVELZOO
ITGR INTEGER HOLDINGS CORPORATION
BX THE BLACKSTONE GROUP L.P.
REZI RESIDEO TECHNOLOGIES
AEYE INC.
BW AUDIOEYE INC
PNTG BABCOCK & WILCOX ENTERPRISES
MRVI PENNANT GROUP
UPST MARAVAI LIFESCIENCES HOLDINGS
NEXT UPSTART HOLDINGS
CLVT NEXT CAPITAL
OGN CLARIVATE PLC
MYPS ORGANON & CO
FRST PLAYSTUDIOS INC
RBA PRIMIS FINANCIAL CORP
CRVO RITCHIE BROS AUCTIONEERS INC.
GAM CERVOMED INC
MDRR GENERAL DE ALQUILER DE MAQUINARIA
SENS MEDALIST DIVERSIFIED REIT INC.
BATRK SENSEONICS HOLDINGS INC.
LIBERTY MEDIA CORP
AtaiBeckley to Participate in the Jefferies Global Healthcare Conferen...
AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London NEW YORK and AMSTERDAM, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that Srinivas Rao, M.D., Ph.D., Co-Founder and Chief Executive Officer, and Kevin Craig, M.D., Chief Medical Officer, are scheduled to participate in the Jefferies Global Healthcare Conference in London, UK. De...
AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Co...
AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights AtaiBeckley solidifies position as a global leader in transformative mental health therapies with a short psychedelic duration BPL-003 (mebufotenin benzoate nasal spray) granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression (TRD) Reported positive topline data from the Phase 2b open-label extension (OLE) study of BPL-003 showing the potential added and sustained antidepressant effects following a second dose in patients with TRD Repo...
AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Lab...
AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression A 12 mg dose of BPL-003 (mebufotenin benzoate nasal spray) administered eight weeks after an initial 12 mg, 8 mg or 0.3 mg dose in the core study of the Phase 2b clinical trial produced additional rapid, clinically meaningful antidepressant effects that were sustained for up to eight weeksPatients who received an active dose of BPL-003 in the core study of the Phase 2b clinical trial (either 8 mg ...
Pennant Group to Participate in the 2025 Stephens Annual Investment Co...
Pennant Group to Participate in the 2025 Stephens Annual Investment Conference EAGLE, Idaho, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announced today that it will participate in the upcoming 2025 Stephens Annual Investment Conference on November 19, 2025. Lynette Walbom, Chief Financial Officer, John Gochnour, Chief Operating Officer, and Andy Rider, President of Pennant’s Senior Living segment, will participate in a fireside chat on November 19, 2025 a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.